Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul;49(4):101447.
doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26.

Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)

Atsushi Tanaka  1 , Yosuke Okada  2 , Keiichi Torimoto  2 , Nozomu Kamei  3 , Hiroyuki Hirai  4 , Teruyuki Kono  5 , Kazuhiro Sugimoto  6 , Hiroki Teragawa  7 , Isao Taguchi  8 , Tatsuya Maruhashi  9 , Satomi Sonoda  10 , Akira Kurozumi  10 , Saori Inagaki  11 , Chikage Oshita  12 , Itaru Hisauchi  13 , Kanae Takahashi  14 , Yukihito Higashi  15 , Michio Shimabukuro  16 , Koichi Node  17 ; PROCEED Trial Investigators
Affiliations
Randomized Controlled Trial

Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)

Atsushi Tanaka et al. Diabetes Metab. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.T. has received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol Myers Squibb, and Novo Nordisk. Y.O. has received honoraria from MSD, Novartis, Mitsubishi Tanabe, Eli Lilly, Novo Nordisk, Kowa, and Sumitomo pharma. N.K. has received honoraria from Eli Lilly and Sumitomo Pharma. KS has received honoraria from Eli Lilly. H.T. has received honoraria from Abbott Medical Japan, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Medtonic, and Nihon Medi-Physics. I.T. has received honoraria from Otsuka, MSD, Astellas, AstraZeneca, Novartis, Daiichi Sankyo, Mitsubishi Tanabe, Eli Lilly, Boehringer Ingelheim, and Takeda; research grants from Boehringer Ingelheim, Mochida, Kowa, and Fukuda Denshi. T.M. has received honoraria from Novartis. K.Takahashi. received outsourcing fees from Organization for Clinical Medicine Promotion. Y.H. has received honoraria and grants from Mitsubishi Tanabe, Teijin, Boehringer Ingelheim, MSD, Sanofi, AstraZeneca, Kyowa Hakko Kirin, Takeda, Astellas, Daiichi Sankyo, Mochida, Nihon Kohden, Shionogi, Nippon Sigmax, Sanwa Kagaku Kenkyusho, Unex, and Kao; honoraria from Radiometer, Omron, Sumitomo Dainippon, Otsuka, Torii, Kowa, Fujiyakuhin, Amgen, Nippon Shinyaku, Itamar, Bayer, Eli Lilly, and Ono. M.S. has received honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Mochida, Novartis, Ono, Sankyo, Tanabe-Mitsubishi, and Teijin. K.N. has received honoraria from MSD, Astellas, AstraZeneca, Novartis, Ono, Daiichi Sankyo, Mitsubishi Tanabe, Eli Lilly, Boehringer Ingelheim, and Takeda; research grants from Asahi Kasei, Astellas, Mitsubishi Tanabe, Teijin, Terumo, Boehringer Ingelheim, Eli Lilly and Company, Mochida, and Fuji; and scholarships from Daiichi Sankyo Healthcare, Teijin, Medtronic, and Bayer. All other authors have nothing to declare.

MeSH terms

LinkOut - more resources